- Home
- NAMS vs NAD Comparison
NAMS vs NAD Comparison
Compare NAMS & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAMS | NAD |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | Netherlands | United States |
| Employees | 100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | NAMS | NAD |
|---|---|---|
| Price | $22.78 | $10.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $46.75 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.35% |
| EPS Growth | ★ 32.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,503,000.00 | N/A |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $540.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.02 | $10.09 |
| 52 Week High | $42.21 | $12.31 |
Technical Indicators
Market Signals| Indicator | NAMS | NAD |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 16.98 |
| Support Level | $21.02 | N/A |
| Resistance Level | $37.26 | $11.97 |
| Average True Range (ATR) | 1.53 | 0.18 |
| MACD | 0.19 | -0.08 |
| Stochastic Oscillator | 32.69 | 2.90 |
Price Performance
Historical ComparisonAbout NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.